Skip to Main Content

Author Details

Vuong Nguyen
The University of Sydney Save Sight Institute
1998
104
21
PMIDPaper TitleJournal TitlePublished Year
34340975Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema.Br J Ophthalmol2023
37505396Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience.Ophthalmol Ther2023
37871984Twenty-four-month real-life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians.Clin Exp Ophthalmol2023
35508721Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion.Eye (Lond)2023
37052611Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.Br J Haematol2023
37069239Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO).Eye (Lond)2023
36536538Subretinal fluid may protect against macular atrophy in neovascular age-related macular degeneration: 5â¿¿years of follow-up from Fight Retinal Blindness registry.Acta Ophthalmol2023
36893432OUTCOMES OF SWITCHING FROM PROACTIVE TO REACTIVE TREATMENT AFTER DEVELOPING ADVANCED CENTRAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.Retina2023
36371040Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! Registry.Ophthalmol Retina2023
36240047Five-year corneal cross-linking outcomes: A Save Sight Keratoconus Registry Study.Clin Exp Ophthalmol2023
36036705Patient-Reported Outcomes in Keratoconus: A Save Sight Keratoconus Registry Study.Cornea2023
35140329Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration.Eye (Lond)2023
35078771Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry.Br J Ophthalmol2023
33196150Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry.Acta Ophthalmol2022
35589075Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.Ophthalmol Retina2022
35869925One-year real-world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion.Clin Exp Ophthalmol2022
36241963Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis.Adv Ther2022
33767407Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry.Eye (Lond)2022
33712484Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry.Br J Ophthalmol2022
33785509Predictors of progression in untreated keratoconus: a Save Sight Keratoconus Registry study.Br J Ophthalmol2022
35307607Characterization of Poor Visual Outcomes of Diabetic Macular Edema: The Fight Retinal Blindness! Project.Ophthalmol Retina2022
35179714Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry.Ophthalmol Ther2022
34907129INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL THERAPY OUTCOMES: Fight Retinal Blindness Registry.Retina2022
35174799THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.Retina2022
35106882Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes.Clin Exp Ophthalmol2022
35080803Quality of life impact of eye diseases: a Save Sight Registries study.Clin Exp Ophthalmol2022
35077009Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery.Clin Exp Ophthalmol2022
35322568Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry.Acta Ophthalmol2022
3451916712-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry.Acta Ophthalmol2022
33960115Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.Acta Ophthalmol2022
34292225THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.Retina2022
32518400Comparison of perimetric Glaucoma Staging Systems in Asians with primary glaucoma.Eye (Lond)2021
33881205Effect of intravitreal injection speed on acute rise in intraocular pressure. The SPEED IOP study.Clin Exp Ophthalmol2021
34730771Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis.Transl Vis Sci Technol2021
34796271Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry.BMJ Open Ophthalmol2021
34129283Neovascular age-related macular degeneration at treatment intervals of 14â¿¿weeks or greater.Clin Exp Ophthalmol2021
34013534Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry.Clin Exp Ophthalmol2021
33935236Comparative Efficacy and Safety of Standard Versus Accelerated Corneal Crosslinking for Keratoconus: 1-Year Outcomes From the Save Sight Keratoconus Registry Study.Cornea2021
34058152Outer Retinal Layer Thickening Predicts the Onset of Exudative Neovascular Age-Related Macular Degeneration.Am J Ophthalmol2021
33219442Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry.Graefes Arch Clin Exp Ophthalmol2021
33332811ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR.Retina2021
33239765Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence.Eye (Lond)2021
33354933Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands.Acta Ophthalmol2021
32826995Response to: "Comment on: 'Comparison of perimetric glaucoma staging systems in Asians with primary glaucoma'".Eye (Lond)2021
32310628FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project.Retina2021
30821728ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.Retina2020
31757494Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry.Ophthalmology2020
31843790Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.Br J Ophthalmol2020
31932092Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.Ophthalmology2020
32073543PREVALENCE AND RISK FACTORS FOR THE DEVELOPMENT OF PHYSICIAN-GRADED SUBRETINAL FIBROSIS IN EYES TREATED FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.Retina2020
  • 1 - 50 of 104

Recommended Authors

Thais F Conti
Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic
Career Start Year 2018
Number of shared co-authors 1
Livia Faes
Eye Clinic, Cantonal Hospital of Lucerne
Career Start Year 2014
Number of shared co-authors 2
Cecilia S Lee
University of Washington
Career Start Year 2014
Number of shared co-authors 10
Freekje van Asten
National Eye Institute, National Institutes of Health.
Career Start Year 2013
Number of shared co-authors 3
Katrin Fasler
University Hospital Zurich, University of Zurich
Career Start Year 2013
Number of shared co-authors 4
Dun Jack Fu
Research Centre, Moorfields Eye Hospital NHS Foundation Trust
Career Start Year 2012
Number of shared co-authors 2
Miranda Buckle
University of Oxford
Career Start Year 2009
Number of shared co-authors 2
Konstantinos Balaskas
University of Manchester
Career Start Year 2009
Number of shared co-authors 8
Mali Okada
Royal Victorian Eye and Ear Hospital
Career Start Year 2008
Number of shared co-authors 7
Robert P Finger
Universitats-Augenklinik Mannheim
Career Start Year 2006
Number of shared co-authors 9
Adam R Glassman
Jaeb Center for Health Research
Career Start Year 2006
Number of shared co-authors 0
Katherine E Talcott
Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic
Career Start Year 2005
Number of shared co-authors 1
Randhir Chavan
Sandwell and West Birmingham Hospitals NHS Trust
Career Start Year 2005
Number of shared co-authors 2
Tiarnan D L Keenan
National Eye Institute, National Institutes of Health
Career Start Year 2005
Number of shared co-authors 6
Richard Gale
Hull York Medical School, University of York
Career Start Year 2003
Number of shared co-authors 7
Wen Xing
Moorfields Eye Hospital NHS Foundation Trust
Career Start Year 2003
Number of shared co-authors 5
Praveen J Patel
NIHR Moorfields Biomedical Research Centre
Career Start Year 2003
Number of shared co-authors 8
Sajjad Mahmood
University of Manchester
Career Start Year 2001
Number of shared co-authors 4
Rishi P Singh
Cleveland Clinic Martin Hospitals, Cleveland Clinic Florida
Career Start Year 2000
Number of shared co-authors 2
Sobha Sivaprasad
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital
Career Start Year 1999
Number of shared co-authors 13
Tunde Peto
Queen's University Belfast
Career Start Year 1999
Number of shared co-authors 7
Robin Hamilton
Moorfields Eye Hospital NHS Foundation Trust
Career Start Year 1998
Number of shared co-authors 4
Clare Bailey
Bristol Eye Hospital
Career Start Year 1997
Number of shared co-authors 4
Stephen J Talks
Newcastle Hospitals NHS Foundation Trust
Career Start Year 1993
Number of shared co-authors 6
Allen C Ho
Wills Eye Hospital/Mid Atlantic Retina
Career Start Year 1992
Number of shared co-authors 2
Faruque Ghanchi
Bradford Teaching Hospitals NHS Foundation Trust
Career Start Year 1992
Number of shared co-authors 3
Michael W Stewart
Mayo Clinic
Career Start Year 1988
Number of shared co-authors 2
Usha Chakravarthy
Queen's University Belfast
Career Start Year 1985
Number of shared co-authors 11
Maureen G Maguire
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1979
Number of shared co-authors 0
Neil M Bressler
Wilmer Eye Institute, Johns Hopkins University School of Medicine
Career Start Year 1979
Number of shared co-authors 5

Collaborators

Mark C Gillies
The University of Sydney Save Sight Institute
Co-authored papers 79
Daniel Barthelmes
University Hospital Zurich and University of Zurich
Co-authored papers 61
Hemal Mehta
The University of Sydney Save Sight Institute
Co-authored papers 24
Vincent Daien
University Hospital Montpellier
Co-authored papers 20
Chui Ming Gemmy Cheung
Singapore Eye Research Institute
Co-authored papers 10
Ian L McAllister
University of Western Australia, Lions Eye Institute
Co-authored papers 10
Javier Zarranz-Ventura
Hospital Clinic of Barcelona, University of Barcelona
Co-authored papers 9
Stephanie L Watson
The University of Sydney, Save Sight Institute
Co-authored papers 9
Kelvin Yi Chong Teo
Singapore Eye Research Institute
Co-authored papers 6
Robyn H Guymer
Royal Victorian Eye and Ear Hospital, the University of Melbourne
Co-authored papers 5
Mehmet Ozturk
Ophthalmology Clinic, Haseki Training and Research Hospital
Co-authored papers 2
Peter McCluskey
Save Sight Institute, University of Sydney
Co-authored papers 2
Jamie E Craig
Flinders Medical Centre, Flinders University
Co-authored papers 1
Robert Kim
University of California
Co-authored papers 1
Ecosse L Lamoureux
Singapore Eye Research Institute
Co-authored papers 1
Mark A Rubin
University of Bern
Co-authored papers 1
Traci E Clemons
The EMMES Corporation
Co-authored papers 1
Caroline C W Klaver
Erasmus Medical Center
Co-authored papers 1
Eva K Fenwick
Singapore Eye Research Institute, Duke-NUS Medical School
Co-authored papers 1
Adnan Tufail
Moorfields Eye Hospital NHS Foundation Trust
Co-authored papers 1
Aaron Lee
Harvard University, Moorfields Eye Hospital NHS Foundation Trust, St. John's Mercy Hospital, University of British Columbia, University of Washington, Washington University in Saint Louis
Co-authored papers 1
Alan L James
Co-authored papers 1
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 1
Giovanni Staurenghi
Eye Clinic, Department of Biomedical and Clinical Science, University of Milan
Co-authored papers 1
Suzann Pershing
Spencer Center for Vision Research, Byers Eye Institute, Stanford University
Co-authored papers 1
Fred K Chen
Royal Perth Hospital
Co-authored papers 1
Release 1.2